ECSP066694A - Hormonas de administración transdérmica que no necesitan potenciadores de penetración - Google Patents

Hormonas de administración transdérmica que no necesitan potenciadores de penetración

Info

Publication number
ECSP066694A
ECSP066694A EC2006006694A ECSP066694A ECSP066694A EC SP066694 A ECSP066694 A EC SP066694A EC 2006006694 A EC2006006694 A EC 2006006694A EC SP066694 A ECSP066694 A EC SP066694A EC SP066694 A ECSP066694 A EC SP066694A
Authority
EC
Ecuador
Prior art keywords
hormones
patch
potentiators
transdermal administration
need
Prior art date
Application number
EC2006006694A
Other languages
English (en)
Inventor
Michael Dittgen
Stefan Bracht
Petra Huber
Thomas Langguth
Dirk Schenk
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066694(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP066694A publication Critical patent/ECSP066694A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a un parche que comprende una capa de droga con un bajo contenido de hormonas, como por ejemplo gestodeno, y opcionalmente un estrógeno (por ejemplo etinilestradiol). Al aplicar el parche a una mujer, se consiguen niveles en plasma de al menos 1,0 ng/ml de gestodeno en condiciones de estado estacionario sin necesidad de incorporar potenciadores de penetración ni mejoradores de permeación en la capa que contiene droga. También son satisfactorios los niveles en plasma de las hormonas que se consiguen durante todo un período de al menos 1 semana, haciendo que el parche se pueda aplicar para utilizarlo en anticoncepción femenina con el concepto de aplicar el parche una vez a la semana
EC2006006694A 2003-12-12 2006-07-11 Hormonas de administración transdérmica que no necesitan potenciadores de penetración ECSP066694A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
EP03078881 2003-12-12

Publications (1)

Publication Number Publication Date
ECSP066694A true ECSP066694A (es) 2006-10-31

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006694A ECSP066694A (es) 2003-12-12 2006-07-11 Hormonas de administración transdérmica que no necesitan potenciadores de penetración

Country Status (15)

Country Link
JP (1) JP4965263B2 (es)
KR (1) KR101168449B1 (es)
CN (1) CN1913878B (es)
AU (1) AU2004298930B2 (es)
BR (1) BRPI0417530B8 (es)
CA (1) CA2549916C (es)
CU (1) CU23868B1 (es)
EA (1) EA011160B1 (es)
EC (1) ECSP066694A (es)
IL (1) IL176112A (es)
MX (1) MXPA06006682A (es)
NO (1) NO341989B1 (es)
NZ (1) NZ548091A (es)
WO (1) WO2005058287A2 (es)
ZA (1) ZA200605713B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100704825B1 (ko) 2003-02-21 2007-04-09 바이엘 쉐링 파마 악티엔게젤샤프트 Ｕｖ 안정성 경피 치료 플라스터
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
FR2900048B1 (fr) * 2006-04-21 2012-11-16 Oreal Compositions comprenant un derive diphenyl-methane hydroxyle
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
WO2012031999A2 (en) 2010-09-06 2012-03-15 Bayer Pharma Aktiengesellschaft Low-dose transdermal patches with high drug release
EP2806862A2 (en) * 2012-01-27 2014-12-03 Agile Therapeutics, Inc. Transdermal hormone delivery
HK1251938A1 (zh) * 2015-05-18 2019-05-03 敏捷治疗公司 避孕组合物及提高效能和调节副作用的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394429B1 (de) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend gestoden
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
NZ240358A (en) * 1990-10-29 1994-09-27 Alza Corp Transdermal contraceptive device comprising (as active agents) an estrogen and a gestodene together with a skin permeation enhancer
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
KR970706805A (ko) * 1994-11-18 1997-12-01 나까토미 히로타카 경피흡수첩부제(percutaneously absorbable patch)
CN1188189C (zh) * 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP4167750B2 (ja) * 1997-04-16 2008-10-22 久光製薬株式会社 経皮吸収用基剤及び該基剤を含有する経皮吸収製剤
JP4399044B2 (ja) * 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
WO2001001990A1 (en) * 1999-07-01 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Adhesive preparation for percutaneous absorption
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
AU2002235155A1 (en) * 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems

Also Published As

Publication number Publication date
CN1913878A (zh) 2007-02-14
EA011160B1 (ru) 2009-02-27
NO341989B1 (no) 2018-03-12
CA2549916C (en) 2013-09-17
KR20060128910A (ko) 2006-12-14
BRPI0417530B8 (pt) 2021-05-25
JP2007513938A (ja) 2007-05-31
NO20062594L (no) 2006-07-10
EA200601089A1 (ru) 2006-12-29
CU20100143A7 (es) 2011-10-31
IL176112A0 (en) 2006-10-05
CA2549916A1 (en) 2005-06-30
AU2004298930B2 (en) 2009-11-26
CN1913878B (zh) 2010-05-26
CU23868B1 (es) 2013-03-27
MXPA06006682A (es) 2006-08-11
KR101168449B1 (ko) 2012-07-25
AU2004298930A1 (en) 2005-06-30
WO2005058287A2 (en) 2005-06-30
JP4965263B2 (ja) 2012-07-04
IL176112A (en) 2011-02-28
ZA200605713B (en) 2008-01-08
NZ548091A (en) 2009-12-24
BRPI0417530A (pt) 2007-03-13
WO2005058287A3 (en) 2006-03-02
BRPI0417530B1 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
CU20100143A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
CY1115064T1 (el) Διαδερμικο συστημα παραδοσης ορμονων χωρις ενισχυτες διεισδυσης
SE0202857D0 (sv) Method and compositions for preventing hormone induced adverse effects
DK0836506T3 (da) Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen
BR0312007A (pt) Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
AR013520A1 (es) Metodo de preparacion de un dispositivo de administracion transdermal, dispositivo de administracion transdermal y utilizacion de un esteroide comoaditivo en un dispositivo de administracion transdermal
KR890011585A (ko) 경피식 피임약제제형
CA3010829A1 (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
MXPA04005211A (es) Sistemas terapeuticos transdermicos que contienen hormona esteroides y monocaprilato de propilenglicol.
AR021459A1 (es) PARCHE QUE CONTIENE ESTRADIOL PARA LA APLICACIoN PERCUTÁNEA DE HORMONAS.
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
ATE382356T1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
MX2007013137A (es) Regimen anticonceptivo con dosificacion de estrogeno ampliada.
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
UY28668A1 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
CU23649B7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
PE20070119A1 (es) Nuevos regimenes para dispositivos de suministro controlado de farmacos para la anticoncepcion
ATE269063T1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam
TH115856A (th) การนำส่งฮอร์โมนผ่านผิวหนังโดยไม่ต้องการสารเพิ่มการแทรกซึม
PL359235A1 (en) Therapeutic agent